{"id":"NCT01686568","sponsor":"Mayo Clinic","briefTitle":"Omega-3 Fatty Acids and Insulin Sensitivity","officialTitle":"Dietary Omega-3 Fatty Acids as a Therapeutic Strategy in Insulin Resistant Humans","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-12-21","primaryCompletion":"2014-10-30","completion":"2015-06-08","firstPosted":"2012-09-18","resultsPosted":"2015-07-10","lastUpdate":"2017-03-03"},"enrollment":31,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Insulin Resistance"],"interventions":[{"type":"DRUG","name":"Omega-3","otherNames":["Essential fatty acids","Omega-3 fatty acids","Omega-3 polyunsaturated fatty acids","PUFAs","Lovaza"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Omega-3","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is being done to understand the effects of dietary omega-3 fats on insulin sensitivity in adult men and women.","primaryOutcome":{"measure":"Insulin Sensitivity by Hyperinsulinemic-euglycemic Clamp at Baseline and 6 Month Follow up","timeFrame":"Baseline, after 6 months of treatment","effectByArm":[{"arm":"Omega-3","deltaMin":10.92,"sd":1.04},{"arm":"Placebo","deltaMin":10.39,"sd":0.76}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["25852206","28424185"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":14},"commonTop":[]}}